Researchers have published results that show encouraging therapeutic options for patients with blood cancer and multiple myeloma after first-line treatment with bispecific antibodies fails. Bispecific antibodies are a type of antibody that can bind to two different antigens at the same time -- they are meant to enhance the immune system's destruction of tumour cells. While new T cell-based immunotherapies, or "T-cell redirection" therapies, such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have revolutionized cancer treatment, doctors still need to determine what second-line treatments (also known as salvage therapy) are effective after a patient relapses. In t
Hence then, the article about researchers report encouraging immunotherapy options for relapsed myeloma patients was published today ( ) and is available onDevdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Researchers report encouraging immunotherapy options for relapsed myeloma patients )